COVID‑19 Vaccination and Usefulness in Prevention of Mortality Among the Elderly: An Analysis
Abstract
Keywords
Full Text:
PDFReferences
Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX,
et al. Safety, tolerability, and immunogenicity of a
recombinant adenovirus type‑5 vectored COVID‑19 vaccine:
A dose‑escalation, open‑label, non‑randomised, first‑in‑human
trial. Lancet 2020;395:1845‑54.
Palacios R, Patiño EG, de Oliveira Piorelli R, Conde MTRP,
Batista AP, Zeng G, et al. Double‑blind, randomized,
placebo‑controlled phase III clinical trial to evaluate the efficacy
and safety of treating healthcare professionals with the adsorbed
COVID‑19 (Inactivated) vaccine manufactured by sinovac ‑
PROFISCOV: A structured summary of a study protocol for a
randomised controlled trial. Trials 2020;21:853.
Wiwanitkit V. COVID‑19, vaccine, safety, adverse effect and
death. Available from: https://www.bmj.com/content/372/bmj.
n149/rr‑11.[Last accessed on 2021 Jan 20].
Knoll MD, Wonodi C. Oxford‑AstraZeneca COVID‑19 vaccine efficacy. Lancet 2021;397:72‑4.
Lipsitch M, Dean NE. Understanding COVID‑19 vaccine
efficacy. Science 2020;370:763‑5.
Shahid Z, Kalayanamitra R, McClafferty B, Kepko D,
Ramgobin D, Patel R, et al. COVID‑19 and older adults: What
we know. J Am Geriatr Soc 2020;68:926‑9.
Kang SJ, Jung SI. Age‑related morbidity and mortality among
patients with COVID‑19. Infect Chemother 2020;52:154‑64.
Torjesen I. Covid‑19: Norway investigates 23 deaths in frail
elderly patients after vaccination. BMJ 2021;372:149.